高职“市场调研”课程实训教学设计

高职“市场调研“实训课程设计直接影响到课程教学效果。在分析国内外高职实训教学模式的现状基础上,强调“以学生为主体“,开展实训课程教学设计,从实训课程设计思路、实训项目主要内容、实训方式、考核方法等几个方面探讨了市场调研课程的实训教学模式。2013年福建省教育厅中青年教师教育科研项目“市场调研课程实训教学模式研究”(JB13676S

高职互联网金融专业人才培养探讨——基于前程无忧网站分析

大数据、云服务、互联网金融等金融创新不断涌现,新的互联网金融机构如雨后春笋般涌现。互联网金融人才的需求也随之产生,本文以前程无忧网站——国内最大的人才招聘网站之一,对金融人才的招聘为分析对象,分析了互联网金融岗位职责及任职条件,特别是高职层次互联网金融人才需求。现在在高职已经开设互联网金融专业,而新的专业的人才培养目标及课程与传统截然不同;本文希望通过分析,便于互联网金融专业在制定金融人才培养计划及设置相关的课程时,提供参考作用。厦门城市职业学院2014年校级课题:“互联网时代厦门市中小银行金融创新”(课题号:KYSK2014-2

阿胶酶解物抗氧化肽的分离与质谱分析

采用阴离子交换纤维及Sephadex G-25柱色谱法对阿胶酶解物进行分离纯化,以DPPH,ABTS法对阿胶酶解物及其不同部位进行体外抗氧化能力测定,从阿胶酶解物中筛选出体外抗氧化活性最强的部位,命名为GFC-1。GFC-1质量浓度为2.0g·L-1时对DPPH清除率为47.95%,0.40g·L-1时对ABTS清除率为97.20%;利用LC-ESI-MS/MS结合TurboSE-QUEST检索软件及Swiss-Prot数据库从GFC-1中鉴定出9个小分子肽,并从中识别出高重复核心序列GPAGPP*GPP*(P*为羟脯氨酸)

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials